Clinical Trials
28 trialsA Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
AbbVie
DETERMINE
Cancer Research UK
LINKER-MM8
Regeneron Pharmaceuticals
A Prospective, Multicenter, Diagnostic Study Evaluating 68Ga-BCMA PET/CT for Targeting BCMA Expression in Multiple Myeloma.
Peking University First Hospital
DETERMINE
Cancer Research UK
The Relapse from MRD Negativity As Indication for Treatment (REMNANT) Study
Oslo University Hospital
KPD Consolidation After ASCT in NDMM Patients
Peking University People's Hospital
A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC
RithMM
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
CURATE.AI Optimized Modulation for Multiple Myeloma
National University Hospital, Singapore
Autologous Transplant for Multiple Myeloma
Masonic Cancer Center, University of Minnesota
Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor
Kiadis Pharma
Mel vs BUCY+VP-16 Conditioning Regimen for MM Undergoing Auto-HSCT
Nanfang Hospital, Southern Medical University
Thalidomide 100 mg/Day Versus Thalidomide 400 mg/Day in Relapse Refractory Multiple Myeloma
Celgene
GERMAIN
University of Jena
Thalidomide-Dexamethasone for Multiple Myeloma
M.D. Anderson Cancer Center
DARA
Vejle Hospital
Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell Malignancies
University of Alabama at Birmingham
Randomized Study of Velcade-based Regimen With Autologous Stem Cell Transplantation in Newly-diagnosed Myeloma Patients
Shanghai Jiao Tong University School of Medicine
Assessment of Molecular Remission by ASO-qPCR After Bortezomib-dexamethasone (Vel/Dex) Followed by ASCT
Tampere University Hospital
TIME-2
Bristol-Myers Squibb
MSC-CY
National Research Center for Hematology, Russia
Thalidomide/Dexamethasone vs MP for Induction Therapy and Thalidomide/Intron A vs Intron A for Maintenance Therapy
Austrian Forum Against Cancer
Study of MAGE-A3 and NY-ESO-1 Immunotherapy in Combo With DTPACE Chemo and Auto Transplantation in Multiple Myeloma
University of Arkansas
Autologous Bone Marrow Transplantation (BMT) Compared With Allogeneic BMT in Multiple Myeloma
Tehran University of Medical Sciences
CU01
WiSP Wissenschaftlicher Service Pharma GmbH
Hematopoietic Stem Cell Transplantation in Myeloma
Azienda Ospedaliera San Giovanni Battista
A Randomized Trial of Human Growth Hormone (hGH) vs Placebo in Intensively Treated Haemato-Oncology Patients.
Royal Marsden NHS Foundation Trust